baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ABBVIE INC/ US00287Y1091 /

2024-04-23 9:05:34 AM	Chg. -0.58	Volume	Bid10:16:02 AM	Ask10:16:02 AM	Market Capitalization	Dividend Y.	P/E Ratio
157.86EUR	-0.37%	0 Turnover: -	157.26Bid Size: 61	158.26Ask Size: 61	278.37 bill.EUR	-	-

GlobeNewswire 04-22 TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...

GlobeNewswire 04-22 Anthos Therapeutics Announces Appointment of Bill Meury as CEO

GlobeNewswire 04-19 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes a...

GlobeNewswire 04-19 Life Science Cares Launches in Switzerland

GlobeNewswire 04-19 Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire 04-19 Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...

GlobeNewswire 04-18 Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial fo...

GlobeNewswire 04-17 Royalty Pharma Declares Second Quarter 2024 Dividend

GlobeNewswire 04-16 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

GlobeNewswire 04-16 OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of C...

GlobeNewswire 04-16 Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

GlobeNewswire 04-15 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...

Newsfile Corp 04-12 Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Acce...

GlobeNewswire 04-09 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, ...

GlobeNewswire 04-09 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

GlobeNewswire 04-08 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...

GlobeNewswire 04-08 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...

GlobeNewswire 04-06 Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...

GlobeNewswire 04-03 Sig Kirk Joins Assertio Board of Directors

GlobeNewswire 04-02 Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over P...

GlobeNewswire 04-02 Abivax reports 2023 financial results and operational update

GlobeNewswire 04-02 OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1...

GlobeNewswire 04-01 SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ADTH, LABP, FUSN

GlobeNewswire 04-01 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent ...

GlobeNewswire 04-01 NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

ABBVIE INC/ US00287Y1091 /

If you wish to receive reply to your feedback, please provide your email address.